. Analysis of p27 kip1 derived from Burkitt's lymphoma cell lines expressing high levels of p27 kip1 , BL40 and BL41, in a cyclin E/cdk2 kinase inhibition assay demonstrated that p27 kip1 is not permanently inactivated since heat treatment can restore the inhibitory activity of p27 kip1 . However, p27 kip1 expressed in these two cell lines is largely sequestered in inactive complexes and we have no evidence that c-myc or EpsteinBarr virus are responsible for the sequestration of p27 kip1 in these two cell lines although c-myc and EBV are two oncogenic agents often associated with Burkitt's lymphomas. Interestingly, we observed that high level p27 kip1 expression often correlated with cyclin D3 overexpression both in vivo and in BL cell lines. The majority of p27 kip1 in BL40 cells was complexed with cyclin D3 indicating that overexpressed cyclin D3 may at least be part of the sequestering activity for the inhibitory function of p27 kip1 . Furthermore, cyclinD3/cdk4 complex could sequester p27 kip1 in a cyclin E/cdk2 kinase assay in vitro. Finally, we show that cyclin D3 transfected into an inducible p27 kip1 cell line could overcome the G1 arrest mediated by p27 kip1 . These results argue that in addition to down-regulation of p27 kip1 expression, some tumour cells can sequester and tolerate the antiproliferative function of p27 kip1 . They also suggest a novel role for the overexpression of D-type cyclins as one pathway allowing tumour cells to overcome the antiproliferative function of p27 kip1 .
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Introduction
The cyclin dependent kinase (cdk) inhibitor p27 kip1 is a member of the cip/kip family which also includes p21 waf1/cip1 and p57 kip2 (Elledge and Harper, 1994 . Members of the cip/kip family share sequence homology and inhibit the kinase activity of a variety of cdks, whereas members of the ink4 family speci®cally inhibit the activity of cdk4 and cdk6. All cdk inhibitors cause G1 arrest when overexpressed in transfected cells.
We previously demonstrated a general inverse correlation between p27 kip1 expression and cell proliferation in 25 dierent normal human tissues, suggesting that p27 kip1 may play an important role in the negative regulation of cell growth . Consistent with this, 27 kip1 is thought to play a central role in the G1 arrest induced by TGFb, rapamycin, cyclic AMP, contact inhibition or serum deprivation (Kato et al., 1994; Nourse et al., 1994; Polyak et al., 1994a,b; Reynisdottir et al., 1995) . Interleukin-2 induced T cell proliferation is also associated with down regulation of p27 kip1 expression Nourse et al., 1994) . Furthermore, the increased body size in p27 kip1 de®cient mice and the development of multiple organ hyperplasia and pituitary tumours in p27 kip1 de®cient mice suggest that p27 kip1 plays an important role in repressing tumour development (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996) . p27 kip1 knock out mice are predisposed to tumours in a variety of tissues especially in response to gamma irradiation and chemical carcinogen treatment. A detailed study of p27 kip1 in heterozygous mice illustrated that p27 kip1 is a haploinsucient tumour suppressor (Fero et al., 1998) .
Deletions, rearrangements or mutations of the p27 kip1 gene have rarely been detected in studies involving over 500 cases of human cancers (Lloyd et al., 1999) . However, recent analyses performed by us and others have established a prognostic value for the expression of p27 kip1 in human breast, colorectal, gastric and small-cell lung carcinomas reviewed in Lloyd et al., 1999) . Consistent with the growth inhibitory function of p27 kip1 , its lack of expression was often observed in approximately 70% of the most malignant tumours examined.
Among the human tissues previously examined the closest inverse correlation between p27 kip1 expression and cell proliferation was seen in the lymph node . This inverse correlation suggested a critical role for the anti-proliferative function of p27 kip1 in the regulation of lymphocyte growth. We, therefore investigated the potential prognostic value of p27 kip1 in human B-cell lympho- 
Results
High levels of p27 kip1 expression in Burkitt's lymphomas in vivo
We ®rst examined the expression of p27 kip1 in normal human lymph nodes using the p27 kip1 -speci®c monoclonal antibodies SX53G8 (shown here) and SX18F7 (data not shown) . Consistent with an antiproliferative function of p27 kip1 in lymphocytes, p27 kip1 expression was readily detected in the follicular center of the lymph node where most cells do not proliferate (Figure 1a ). In contrast, most cells in the germinal center are proliferating and did not express detectable levels of p27 kip1 . The few positive cells in the germinal center are believed to be nonproliferative lymphocytes. The close correlation between lack of detectable p27 kip1 expression and proliferation in normal lymphocytes and previous identi®cation of p27 kip1 as an independent prognostic marker for some epithelial cancers prompted us to examine the expression of p27 kip1 in a panel of B-cell lymphomas. We analysed 90 cases of B-cell lymphomas (Table 1) , including 39 cases of small B-cell lymphoma and 51 cases of large B-cell lymphoma.
Among the small B-cell lymphomas, 93% (14/15) of follicular lymphomas and 94% (16/17) of low grade Bcell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphomas expressed detectable p27 kip1 (Table 1 ). An example of p27 kip1 expression in a follicular small B-cell lymphoma is shown in Figure  1b . In contrast, only 28% (2/7) of mantle cell lymphomas had detectable p27 kip1 expression. These results support the idea that p27 kip1 expression is often observed in low malignancy tumours independent of tumour cell type.
In agreement with their high degree of malignancy, the number of p27 kip1 -expressing lymphomas dropped signi®cantly in the 51 cases of large B-cell lymphomas analysed. 0% (0/12) of diused large B-cell lymphoma examined expressed p27 kip1 (for an example, see Figure  1c ) and only 16% (4/25) of high grade MALTlymphoma expressed p27 kip1 . Considering their highly malignant nature, it was therefore very surprising to detect p27 kip1 expression in 50% (7/14) Burkitt's lymphoma cases (for an example, see Figure 1d ). Despite the number of cases examined for each type of lymphoma being relatively small, these results clearly suggest that, with the exception of Burkitt's lymphoma, p27 kip1 status correlates with malignancy in B-cell lymphomas. p27 kip1 may therefore also have a useful role as a prognostic marker in these malignancies. (Figure 2a) , top panel).
The unusually high level of p27 kip1 expression tolerated in some Burkitt's lymphoma cell lines suggests highly malignant tumours utilize pathways other than down-regulation of expression to overcome the growth inhibitory activity of p27 kip1 . Burkitt's lymphomas are characterized by high c-myc oncoprotein expression level due to reciprocal translocation of the c-myc gene to immunoglobulin enhancer sequences. C-myc activation or induction of its expression can overcome cell cycle control mediated by p27 kip1 in rat-1 cells by either stimulating its degradation (Muller et al., 1997) or its sequestration (Vlach et al., 1996) . In addition, some Burkitt's lymphomas are infected with the large DNA tumour virus Epstein-Barr virus (EBV). kip1 sequestration activity was measured in a cyclin E/cdk2 kinase assay using histone H1 as a substrate
However, it is not known whether EBV-encoded proteins, like adenovirus E1A or human papilloma virus E7, directly inactivate p27 kip1 (Mal et al., 1996; Zerfass-Thome et al., 1996) . So we compared p27 kip1 expression with c-myc or EBV status in the BL cell lines. Although c-myc expression was variable ( Figure  2a , middle panel), it did not correlate with p27 kip1 expression from the same set of cell lysates. For instance, dierent amounts of c-myc were expressed in BL2, AKATA, and NAMALWA cells but the expression level of p27 kip1 in these three cell lines are very similar (Figure 2a , middle and top panels). The lack of correlation between c-myc and p27 kip1 expression can also be seen in BL2 and BL41 cell lines since both cell lines express a similar amount of c-myc but the level of p27 kip1 detected in BL41 cells is much higher than that in BL2 cells. Therefore, the expression level of p27 kip1 in BL cells does not correlate with that of cmyc oncoprotein.
The EBV status in ten BL cell lines used in this study was con®rmed by the expression of EBV protein EBNA1. Six of the ten BL lines express EBNA1 ( kip1 is also independent of the presence of EBV.
The anti-proliferative function of p27 kip1 is inactivated by sequestration in Burkitt's lymphoma cell lines BL40 and BL41
The best known function of p27 kip1 is its ability to inhibit cell growth. In response to mitogenic stimuli such as PMA, p27 kip1 expression is down-regulated in human primary B cells ( One way BL cells may tolerate the growth inhibitory function of p27 kip1 is to eliminate its inhibitory activity on cyclin dependent kinases. Potential mechanisms accounting for p27 kip1 inactivation include mutation, permanent modi®cation or sequestration by cellular factors. We explored these possibilities by analysing the inhibitory activity of p27 kip1 derived from some BL cell lines using a cyclin E/cdk2 kinase assay. p27 kip1 in BL40 cells did not inhibit cyclin E/cdk2 kinase activity ( Figure 2d , lane 2) whilst under the same condition, the p27 kip1 derived from primary human B-cells signi®cantly inhibited cyclin E/cdk2 kinase ( Figure 2d , lane 1). This dierence was not due to variations in p27 kip1 levels as similar amounts were expressed in both cells types (Figure 2b, right panel) . Therefore, p27 kip1 in BL40 cells is unable to inhibit cyclin E/cdk2 kinase activity. Similar results were obtained with other p27
kip1 -overexpressing BL cell lines such as BL41 ( Figure 3a , lane 5; and data not shown).
To further dissect the mechanisms underlying p27 kip1 inactivation in p27 kip1
-overexpressing BL cells, we used the heat-stable property of p27 kip1 (Polyak et al., 1994b; Toyoshima and Hunter, 1994) . If p27 kip1 was inactivated by mutation or permanent modi®cation, p27 kip1 obtained from a heat-treated lysate would still be inactive. By contrast, if p27 kip1 's kinase inhibitory activity was blocked by sequestration in cells like BL40 then heat treatment may destroy the sequestering activity and release p27 kip1 's kinase inhibitory activity. In contrast to untreated BL40-derived p27 kip1 , heattreated BL40-derived p27 kip1 signi®cantly inhibited cyclin E/cdk2 kinase activity (Figure 3a , compare lanes 2 and 3). Although p27 kip1 levels often seem to be decreased after heat treatment it still eectively inhibited the kinase activity ( Figure 3b , compare lanes 1 and 2; and Figure 3a and c, lanes 3). Furthermore, the kinase inhibitory activity of heat-treated BL40 cell lysate could be abrogated by immunodepleting p27 kip1 with anti-p27 kip1 antibody coupled protein G-beads (for p27 kip1 level see Figure 3b , lane 3; for kinase assay see Figure 3c , lane 4). These experiments demonstrate that the kinase inhibition in these experiments is due to p27 kip1 . In addition, this protein has not been inactivated in BL40 cells by mutation or permanent modi®cation but by a sequestration activity which is not present in primary B cells. This conclusion was supported by the observation that the expression levels of other cyclin E/cdk2 inhibitors such as p21 cip1 ( Figure  3d ) and p57 kip2 (data not shown) were almost undetectable in BL40 and BL41 cells. Moreover, p27 kip1 's inhibitory activity was restored by heat treatment and removed by pre-incubating untreated cell lysate with heat-treated lysate (at a 2 : 1 ratio) prior to the addition of the kinase (Figure 3a, lane 4) . Similar results were seen when histone H1 was used as substrate instead of pRb (data not shown). Preincubation of untreated BL40 lysate with human primary B-cell lysate also abrogated the inhibitory activity of p27 kip1 in the primary B-cell lysate ( Figure  2d, lane 3) . Furthermore, the ability of untreated BL40 lysate to sequester the inhibitory activity of p27 kip1 was speci®c. It was not due to some kind of unspeci®c BL40 endogenous histone H1 kinase activity since the untreated BL40 lysate on its own neither signi®cantly phosphorylated histone H1 (Figure 3e , lane 1) nor Rb (data not shown).
Knowing that p27 kip1 's growth inhibitory activity was sequestered in BL40 cells, it was important to investigate whether the sequestration activity could be observed in other p27 kip1 overexpressing cell lines. Like BL40 cells, untreated BL41 lysate could not inhibit cyclin E/cdk2 kinase activity (Figure 3a , lane 5) and the untreated lysate could sequester p27 kip1 released in heat-treated lysate (Figure 3a, compare lanes 6 and 7) . In vitro studies have shown that p27 kip1 inhibits cell growth through its ability to inhibit cyclin E/cdk2 or cyclin A/cdk2 kinase activity. Interestingly, cyclin E/ cdk2 also phosphorylates p27 kip1 at threonine residue 187 and triggers its degradation (Shea et al., 1997) . Therefore, one of the potential mechanisms for the Burkitt's lymphoma cells to express high levels of p27 kip1 may be due to the lack of cyclin E/cdk2 kinase activity. High levels of cyclin E have been linked to the down regulation of p27 kip1 in young breast cancer patients (Porter et al., 1997) . To test this hypothesis, cyclin A, cyclin E and cdk2 expression levels were investigated in the chosen panel of Burkitt's lymphoma cell lines. Despite a variation in cyclin A, cyclin E and cdk2 expression levels, they do not correlate with that of p27 kip1 in these cell lines (Figure 4a ). Apart from cyclin E/ cdk2 or cyclin A/cdk2, p27 kip1 can also bind to D-type cyclins and cdk4 or cdk6 (Polyak et al., 1994b) . A correlation between p27 kip1 and cyclin D1 overexpression exists in human breast tumours . Therefore, we investigated the expression of Dtype cyclins in the panel of BL cell lines. p27 kip1 expression levels mostly correlated with cyclin D3 (Figure 4b ). This was observed for BL40, DG75, BL41 and AKATA cell lines. In all cell lines tested, cdk4 expression was very similar and cdk6 did not correlate with p27 kip1 expression levels. Cyclin D2 expression does not correlate with that of p27 kip1 since only BL72 expressed detectable cyclin D2. Cyclin D1 was not detected in this set of cell lines (data not shown).
Interestingly, we found that BL41, DG75 and sometimes NAMALWA and RAEL express an alternative cyclin D3 form. p27 kip1 immunoprecipitation in BL41 and DG75 cells showed that these other cyclin D3 forms also bound p27 kip1 (Figure 4c ). Hence, these alternative cyclin D3 forms may play an oncogenic role in these cell lines by sequestering p27 kip1 . However, the precise roles of these alternative cyclin D3 forms in regulating the growth inhibitory activity of p27 kip1 in BL cells are currently under investigation.
Since there is a correlation between p27 kip1 and cyclin D3 expression levels in BL cell lines it was important for us to determine whether such a correlation also exists in vivo. Six of the p27 kip1 -expressing Burkitt's lymphomas were examined for the expression of cyclin D3 and 4/6 were found to express cyclin D3 at a high level. An example of this study is shown in Figure 5 . These observations are in agreement with those made in the BL cell lines, demonstrating that cultured BL cell lines can be used as an experimental model.
Cyclin D3/cdk4 can sequester the growth inhibitory activity of p27 kip1
It has been shown in vitro that binding of p27 kip1 to cyclin D1/cdk4 prevents p27 kip1 from binding to and inhibiting cyclin E/cdk2 or cyclin A/cdk2 kinases (Reynisdottir et al., 1995) . Overexpression of D-type cip1 expression in some BL cell lines (e) A cyclin E/cdk2 H1 kinase assay demonstrating the lack of residual kinase activity in BL40 cell lysate p27 kip1 inhibition in Burkitt's lymphoma K Barnouin et al cyclins may therefore account for the p27 kip1 sequestering activity in BL40 cells. Since p27 kip1 inhibitory activity is inactivated by sequestration in BL40 cells and high p27 kip1 expression levels is associated with cyclin D3 overexpression, we hypothesized that active cyclin D3/ cdk4 may sequester p27 kip1 from cyclin E/cdk2 and inactivate p27 kip1 . To test this hypothesis we immunoprecipitated cyclin D3 from BL40 cell lysate and analysed the immunoprecipitates for cyclin D3 and p27 kip1 . Cyclin D3 was eciently immunoprecipitated in this experiment (Figure 6a, left panel) . The majority of p27 kip1 in BL40 cells was co-immunoprecipitated with cyclin D3 since there was no detectable p27 kip1 left in cyclin D3 immunodepleted cell lysate (Figure 6a , right panel). Moreover, cyclin D3 expressed in BL40 cells might be in excess as the third round of sequential immunoprecipitation of cyclin D3 failed to pull down any p27 kip1 (Figure 6a , left panel). This ®nding was con®rmed by immunoprecipitating p27 kip1 in BL40 cells and measuring the amount of cyclin D3 co-immunoprecipitated with it. There was still a signi®cant amount of cyclin D3 left in p27 kip1 -immunodepleted BL40 lysate (Figure 6b ). These results indicate that cyclin D3 may be in excess of p27 kip1 and may be responsible for the p27 kip1 sequestration activity in BL40 cells.
To test the hypothesis that cyclin D3/cdk4 sequesters p27 kip1 inhibitory activity, an in vitro cyclin E/cdk2 kinase assay was performed. Histone H1 was used as substrate since it is known that cyclin D3/cdk4 can only phosphorylate Rb but not histone H1 in vitro (Matsushime et al., 1992) (Figure 7a,b, lanes 3) . Therefore, the kinase activity measured on histone H1 would re¯ect the kinase activity of cyclin E/cdk2 but not cyclin D3/cdk4, allowing us to assess the sequestering activity of cyclin D3/cdk4 on p27 kip1 . In addition, cyclin D3 and cdk4 did not have any kinase activity alone (Figure 7a , lanes 1 and 2). Cyclin D3, cdk4 or cyclin D3/cdk4 used in this experiment were produced in a bacculovirus system. The kinase activity of cyclin D3/cdk4 was con®rmed using GST-Rb as a substrate (Figure 7a , lane 3). The ability of cyclin D3/cdk4 to sequester p27 kip1 activity was tested by ®rst incubating cyclin D3/cdk4, cyclin D3 or cdk4 with heat-treated BL40 cell lysate and then reincubated in the presence of cyclin E/cdk2. Preincubation of cyclin D3/cdk4 but not cyclin D3 or cdk4 alone with heat-treated BL40 cell lysate blocked the p27 kip1 inhibitory activity on cyclin E/cdk2 kinase ( Figure 7b , lanes 4 ± 6). Importantly, cyclin D3/cdk4 did not phosphorylate the substrate histone H1 ( Figure  7b, lane 3) , demonstrating that the observed kinase activity (Figure 7b , lane 6) was due to the ability of cyclin D3/cdk4 to sequester p27 kip1 inhibition over the cyclin E/cdk2 kinase activity. Pre-incubation of cyclin D3/cdk4 with active GST-p27 kip1 (Figure 7c , lane 1) also released the inhibition of cyclin E/cdk2 kinase. Thus, cyclin D3/cdk4 was able to speci®cally sequester p27 kip1 activity (Figure 7c , lane 2).
To further investigate the role played by cyclin D3 in p27 kip1 sequestration, we constructed a p27 kip1 -Ecdysone inducible system in the human lung carcinoma cell line H1299 under ponasterone A control. Using dierent concentrations of ponasterone A, the expression of p27 kip1 was induced to a similar level as in BL40 cells with 0.5 M ponasterone A (Figure 8a,b ). Increased 
Analysis of p27
kip1 expression compared to that of cyclin A, cyclin E and cdk2 (a) or to cyclin D2, cyclin D3, cdk4 and cdk6 (b) in a panel of BL cell lines. (c) wild type or alternative forms of cyclin D3 derived from BL40, BL41 and DG75 were detected by an anti-cyclin D3 antibody in the precipitates pulled down by an anti-p27 kip1 antibody p27 kip1 inhibition in Burkitt's lymphoma K Barnouin et al p27 kip1 expression caused G1 arrest in over 70% of H1299 cells as measured by FACS analysis (Figure 8c , CD20 negative population). Therefore, this cell system allowed us to investigate whether cyclin D3 overexpression alone could overcome G1 arrest induced by p27 kip1 . Cyclin D3 expression plasmid or the empty control vector plasmid (CMV) were transiently transfected into the p27 kip1 -inducible cell line in the presence of cell surface marker CD20 with and without p27 kip1 induction. The level of ectopically expressed cyclin D3 in the p27 kip1 inducible cell line was comparable to the level of endogenously expressed cyclin D3 in BL40 cells (Figure 8b ). The CD20 positive population was considered as cyclin D3 transfected cells and the eect of cyclin D3 on the cell cycle progression was analysed among these cells. The expression of cyclin D3 signi®cantly reduced the number of cells arrested at G1 upon the induction of p27 kip1 expression from 70 to 60% (Figure 8c , see also bar charts). In contrast, the CD20-negative cells did not express cyclin D3 and undergo G1 arrest upon induction of p27 kip1 ( Figure 8c, right panel) . These results demonstrate that cyclin D3 overexpression can overcome p27 kip1 's growth inhibitory activity in vitro and in vivo. It is therefore likely that cyclin D3 overexpression may be responsible for the sequestration and inactivation of p27 kip1 in Burkitt's lymphoma cells.
Discussion
In this study, we investigated the potential prognostic value of p27 kip1 in human B-cell lymphomas. In agreement with a recent report by Sanchez-Beato et al. (1997) , our observations suggest that with the exception of Burkitt's lymphoma (BL), there is an inverse correlation between p27 kip1 expression level and the degree of malignancy in B-cell lymphomas. Although the number of cases in this study is relatively small it clearly indicated that, like in human breast and colorectal cancers, the expression level of p27 kip1 could be a useful independent prognostic marker for human B-cell lymphomas.
The unusually high frequency of Burkitt's lymphomas overexpressing p27 kip1 suggested that some highly malignant tumours may use alternative pathways other than down-regulation of expression to tolerate p27 kip1 's growth inhibitory activity. This is particularly interesting since about 30% of highly malignant breast and colorectal tumours also overexpress p27 kip1 . Hence, understanding how p27 kip1 can be tolerated in human Burkitt's lymphomas may allow us to comprehend how p27 kip1 's growth inhibitory activity is regulated in human tumours.
To investigate how some BL may overcome p27 kip1 -mediated growth arrest we used a panel of BL-derived cell lines as an experimental system. Although the results derived from the BL cell lines is statistically insigni®cant, it is interesting to note that like Burkitt's lymphomas in vivo, around half of the BL cell lines overexpress p27 kip1 . This observation led us to use a few of the p27 kip1 overexpressing BL cell lines to investigate activities which can abrogate the growth inhibitory function of p27 kip1 . In an in vitro cyclin E/cdk2 kinase assay, it was evident that the overexpressed p27 kip1 derived from the BL cell lines such as BL40 and BL41, was unable to inhibit cyclin E/cdk2 kinase activity. This was in contrast to p27 kip1 produced in primary B cells which inhibited the cyclin E/cdk2 kinase activity under the same condition (see Figure 2d) . Interestingly the lack of p27 kip1 inhibitory activity derived from BL40 and BL41 cells was not due to mutation or permanent inactivation on p27 kip1 proteins since heat treatment can restore the inhibitory activity of p27 kip1 (Figure 3a) . These results argue that overexpressed p27 kip1 had lost its growth inhibitory activity in the BL cell lines tested and the sequestering activity of p27 kip1 in these cells are sensitive to heat. In order to identify the sequestering activity expressed in BL cells, we ®rst investigated the potential correlation between the expression levels of p27 kip1 and the oncogene c-myc and the DNA tumour virus EBV. We did not ®nd any correlation between the expression of p27 kip1 and cmyc or EBV protein (Figure 2a) . Nevertheless, this does not exclude the possibility that c-myc or EBV may have an eect on the growth inhibition function of p27 kip1 . However, further experimental evidence is required to elucidate this issue.
Apart from c-myc and EBV, we also examined in the BL cell lines used in this study the expression level of p27 kip1 and its partner proteins the cyclins and cdks (Figure 4) . A correlation between p27 kip1 and cyclin D3 expression levels was found both in BL cell lines and Burkitt's lymphomas in vivo. Although the correlation was not absolute, the biochemical evidence provided in this study suggested that cyclin D3 overexpression could sequester the growth inhibitory activity of p27 kip1 . First, it was observed that the majority of p27 kip1 expressed in BL40 cells was associated with cyclin D3. Furthermore, we showed that the amount of cyclin D3 expressed in BL40 cells was in excess. These ®ndings provide a potential molecular basis for cyclin D3 to sequester p27 kip1 in BL40 cells ( Figure 6 ). Second, pre-incubation of p27 kip1 with cyclin D3/cdk4 can sequester p27 kip1 from inhibiting cyclin E/cdk2 kinase activity in vitro ( Figure  7b ,c), illustrating that cyclin D3/cdk4 may sequester p27 kip1 and prevent it from inactivating cyclin E/cdk2 or cyclin A/cdk2 compexes in vivo. Third, cyclin D3 overexpression was able to overcome the G1 arrest mediated by p27 kip1 overexpression in a p27 kip1 -inducible cell line. The latter indicate cyclin D3 overexpression is sucient to overcome p27 kip1 's growth inhibitory activity in cells in vivo (Figure 8 ). These results argue that the high frequency of cyclin D3 overexpression may be partly responsible for sequestering p27 kip1 's growth inhibitory activity in Burkitt's lymphomas. However, it was interesting to note that cyclin D3/cdk4 failed to sequester p27 kip1 's activity in vitro when cyclin E/cdk2 was pre-incubated with p27 kip1 from heat-treated BL40 cell lysate or kip1 before the incubation with cyclin D3/cdk4 (data not shown). This result would suggest that once p27 kip1 is in complex with cyclin E/ cdk2, its inhibition of cyclin E/cdk2 cannot be easily displaced with the addition of cyclin D3/cdk4 in vitro. This observation indicated that in Burkitt's lymphoma cell lines such as BL40 and BL41, the overexpressed cyclin D3 must be able to limit the amount of p27 kip1 from binding to cyclin E/cdk2 and inhibit its kinase activity. Further studies are needed to address this issue.
The data presented in this study is consistent with our recent ®nding that there is a good correlation between p27 kip1 and cyclin D1 overexpression in human breast tumours . It is therefore possible that during tumour development, selected overexpression of D-type cyclins may allow tumour cells to titrate out the growth inhibitory function of p27 kip1 . Although we do not yet know the precise regulation of D-type cyclin overexpression and its association with high levels of p27 kip1 , it was recently reported that p27 kip1 overexpression can induce the expression of endogenous cyclin D1 and D3 in Rat-1 cells (Vlach et al., 1996) . Furthermore, it has also been demonstrated that either p21 cip or p27 kip1 are required for D-type cyclin expression and the up-regulation of cyclinD/cdk4 kinase activity in mitogen stimulated mouse ®broblast cells (Cheng et al., 1999) . All these ®ndings suggest that D-type cyclins overexpression could be one pathway by which tumour cells acquire proliferative capacity. This overexpression would also complement additional p27 kip1 -inactivating events such as its down regulation of expression which have been observed in non-BL malignant B-cell lymphomas Sanchez-Beato et al., 1997) . This hypothesis suggests a novel function for D-type cyclins in human tumour development and may help us to understand why, of the cyclins, it is overexpression of the D-type cyclins that is the most common abnormality in human cancer.
Materials and methods

Cell lines and antibodies
Human Burkitt's lymphoma (BL) cell lines were maintained in RPMI supplemented with 10% FCS and antibiotics. Primary B cells were prepared from buy coat residues as previously described (Sinclair and Farrell, 1995) . Anti-p27 kip1 and anti-cyclin D3 monoclonal antibodies, respectively SX53G8 and DCS-22, were described previously (Bartkova et al., 1996; Fredersdorf et al., 1997) . Rabbit polyclonal antibody to cyclin D1 was a gift from Dr G Peters. A human polyclonal anti-sera was used to detect EBNA1. Anti-c-myc antibody used was 9E10. The remaining antibodies were purchased from either Santa Cruz Biotechnology, Inc or Pharmingen.
Immunoblotting BL cells were seeded at a concentration of 1610 5 cells/ml. Twenty-four hours later the cells were serum stimulated (serum levels increased to 20%) and harvested 12 h after that. The growth condition was critical for the detection of c-myc and cyclin E expression. The BL cells were lysed with sample buer without reducing agent, boiled and sonicated prior to protein concentration determination with PIERCE BCA protein assay kit. b-Mercaptoethanol was added to the lysates and reboiled prior to loading on SDS-polyacrylamide gels. p27 kip1 -inducible cell line (H1299-p27 kip1 ) were lysed with RIPA buer. For immunoblotting, 30 ± 50 mg lysate was loaded and analysed by SDS ± PAGE and the resulting blots were probed with the required primary and secondary antibodies.
Coupling of monoclonal antibodies to protein G-beads and sequential immunoprecipitation of cyclin D3 or p27 kip1 Puri®ed monoclonal antibodies were coupled to protein Gbeads using a method essentially as described (Harlow and Lane, 1988) . Brie¯y, puri®ed antibodies bound to protein Gbeads were washed four times with 10 ml 0.1 M sodium borate, pH 9.0. Cross-linking was done with dimethylpimilimidate dihydrochloride (Sigma) by dissolving 0.5 g in 40 ml 0.1 M sodium tetraborate, pH 8.9 and 10 ml 0.1 M sodium borate, pH 8.9. The beads were immediately added to this solution and incubated on a rotating wheel for 1 h at room temperature. The beads were then resuspended in 0.2 M ethanolamine pH 8.0 and incubated at room temperature on a rotating wheel for another hour. The beads were stored in p27 kip1 inhibition in Burkitt's lymphoma K Barnouin et al PBS containing 0.01% merthiolate until needed. For sequential immunoprecipitation lysates were incubated on a rotating wheel for 2 h at 48C. The supernatant was added to a fresh set of beads and incubated as previously. The latter step was repeated until most of the cyclin D3 or p27 kip1 was removed by this treatment.
Cyclin E/cdk2 histone H1/Rb kinase assay Histone H1 and GST-Rb C-terminal fragment (763 ± 923) kinase assays were performed as described (Godden-Kent et al., 1997) . SF9 insect cells were co-infected with bacculovirus expressing recombinant cdk2 and Myc epitope (9E10)-tagged human cyclin E. After insect cell lysis cyclin E-cdk2 complexes were immunoprecipitated with 10 mg puri®ed 9E10 antibody and 20 ml pre-equilibrated sepharose G-beads (Pharmacia) at 48C on a rotating wheel for 2 h in the HB buer described (Godden-Kent et al., 1997) and used as kinase. Cyclin D3/cdk4 kinase was prepared in a similar manner with the 9E10 tag being attached to cyclin D3. For kinase inhibition assays the kinase lysate was incubated with 100 ng GST-p27 kip1 , or with 100 mg protein of cell lysates derived from BL40, BL41 or primary B cells for 10 min at 278C prior to immunoprecipitation. Heat-treated lysates were prepared by heating at 958C for 5 min and the protein aggregates were spun down. Nearly all the p27 kip1 was retained in an active form in the supernatant and was then used in a kinase assay referred to as heat-treated lysate. In the sequestration experiment, 200 mg of untreated BL40 or BL41 cell lysate were incubated with the equivalent of 100 mg of heat-treated BL40/BL41 or 100 mg primary B cell lysates as indicated at 278C for 10 min. The kinase lysate was added, the mixture was then reincubated at 278C for 10 min and immunoprecipitated with 9E10 antibody. The kinase assay was performed as described (Godden-Kent et al., 1997) .
Construction of p27
kip1 inducible cell line, DNA transfection and FACS analysis Cells were transfected using the calcium phosphate method as described (Hsieh et al., 1997) . The p27 kip1 inducible H1299, a human lung carcinoma cell line which lacks p53, was engineered according to Invitrogen's instructions for the Ecdysone system. p27 kip1 -inducible cells ( 5610 5 ) were co-transfected with 2 mg CD20 and 20 mg empty CMV plasmid or 20 mg cyclin D3 CMV plasmid 6 ± 8 h prior to induction with 0, 0.2, 0.5, or 1.5 mM ponasterone A (PA). The cells were harvested 24 h later and prepared for FACS analysis as described (Hsieh et al., 1997) using Becton Dickinson FACS machine.
Immunohistochemistry
Immunohistochemistry was performed as described previously (Bartkova et al., 1996; Fredersdorf et al., 1997) . Brie¯y, after dewaxing, endogenous peroxidase was blocked using hydrogen peroxide in methanol for 20 min. A microwave antigen retrieval protocol and immunostaining was performed using primary antibody at a dilution of 1 in 5 of supernatant and overnight incubation at 48C. Speci®c binding was detected with an ABC peroxidase system using diaminobenzidine as substrate. Sections were then counter stained with haemotoxylin, mounted and examined by bright ®eld microscopy.
